T3 Pharma closes CHF 25 million financing round: the advisor

T3 Pharmaceuticals, a Swiss biotech company that promotes immuno-oncology with its bacteria-based protein delivery platform, closed its third round of financing of CHF 25 million. The financing was led by existing investors, including the Boehringer Ingelheim Venture Fund (BIVF), Reference Capital, Wille Finance and private investors, all of whom participated in the financing round. With this latest financing, T3 Pharma’s total financing has increased to CHF 40 million since the company was founded in 2015. T3 Pharma will use the funds primarily to advance its lead candidate, T3P-Y058-739, through clinical trials. The start of the phase 1/2 clinical trial on solid tumors is planned for early 2021.

The advisor 

VISCHER advises T3 Pharmaceuticals on all legal issues in connection with the transaction. The team consists of Christian Wyss (Partner, Corporate / M&A – pictured), Pauline Pfirter (Associate, Corporate / M&A), Ruben Masar (Associate, Corporate / M&A), and Gian Geel (Associate, Employment).

T3 Pharma closes CHF 25 million financing round: the advisor

FabioAdmin

Legalcommunity.ch

Launched in 2020 by LC Publishing Group, it is the first digital portal addressed to the Swiss legal market.
In terms of contents, the website focuses on both law firms and in-house legal departments, covering the latest news and rumors on deals and operations (and the related advisors) as well as on lateral hires, moves and new appointments and providing insights, analytical data and opinions on the professions’ main trends and topics (Ai, innovation, etc.).

For further information, please visit the Group’s website www.lcpublishinggroup.com

LC Publishing Group S.p.A. – Via Tolstoi 10 – 20146 Milano – Tel. 0236727659 – C.F./P.IVA 07619210961
REA 1971432 Registro delle Imprese di Milano – Cap. Soc. Euro 50.000,00 i.v.

Copyright 2022 © All rights Reserved. Design by Origami Creative Studio

SHARE

Share on linkedin
Share on twitter
Share on facebook
Share on whatsapp
Share on email
Share on telegram